ARTICLE | Company News
Vanda, Eli Lilly deal
April 23, 2012 7:00 AM UTC
Eli Lilly granted Vanda exclusive, worldwide rights to develop and commercialize VLY-686, a small molecule neurokinin 1 (NK1) substance P receptor (TACR1) antagonist. Vanda said potential indication...